Bruce D. Weintraub, MD
President & CEO
has more than 30 years experience in a biomedical research career that has focused on molecular, cellular, clinical and therapeutic aspects of glycoprotein hormones, related growth factors, thyroid hormone and their receptors.
is the author of over 300 scientific
papers, reviews and book chapters.
In addition has several issued and pending patents related to the cloning of the human TSH beta subunit, development of recombinant TSH, and development of superactive analogs of TSH, gonadotropins and related cystine knot growth factors.
is well known for his
basic science work related to pituitary and recombinant TSH synthesis, glycosylation and action, affinity chromatography as well as clinical aspects of syndromes of inappropriate TSH secretion.
In addition he
was among the first to recognize and define the clinical and molecular aspects of thyroid hormone resistance, TSH- producing pituitary tumors and ectopic production of placental hormones and free subunits by various tumors.
is particularly recognized for his
role as coinventor, codeveloper and a leading investigator in the international clinical trials of recombinant TSH, approved by the FDA
in 1998 for the diagnosis of thyroid cancer, which has revolutionized the approach world -wide to that disease.
Dr. Weintraub obtained his BA from Princeton University magna cum laude where he was elected to Phi Beta Kappa and his MD from Harvard University cum laude where he was elected to Alpha Omega Alpha.
His postdoctoral clinical and basic science training were at Harvard and the National Insitutes of Health and he later served as Assistant Professor at Harvard.
In 1972 he became the first Director of the NIH Endocrinology Training Program and later Chief of its Molecular and Cellular Endocrinology Branch, positions he held until 1995.
In both these positions he helped train a generation of leading international academic and clinical endocrinologists.
From 1996- 2001 he was Professor of Medicine at the University of Maryland at Baltimore, Chief of the Laboratory of Molecular Endocrinology of the Institute of Human Virology of the University of Maryland Biotechnology Institute and Director of the Thyroid Cancer Program of the Greenebaum Cancer Center.
He has received numerous international awards and lectureships, is a member of many scientific research organizations, served on several journal editorial boards as well as on several advisory committees to NIH and various universities.
He has also served on the Council of the Endocrine Society and the American Thyroid Association as well as President of the Maryland Endocrine Society.
She then joined Dr. Weintraub
and Dr. Szkudlinski at the Institute of Human Virology
, University of Maryland, Baltimore
and contributed to the elucidation of the mechanism of activation of the TSH receptor.